Hepatology

Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.

Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.

A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.

Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

A national study found comorbidities may drive worse long-term survival among patients with MASH awaiting or undergoing liver transplant.

Global third-dose hepatitis B (HepB3) vaccine coverage reached 81.8% in 2023, but persistent gaps in Africa and South Asia threaten WHO elimination goals.

MASLD was linked to higher odds of EoE and reflux-related diseases, suggesting metabolic dysfunction may contribute to esophageal disease.

MASLD/MASH was associated with higher mild cognitive impairment risk and lower dementia odds, but competing risks may explain the latter finding.

A recent study found semaglutide more than doubled the likelihood of MASH resolution, but it did not significantly improve fibrosis.

A new review argues that bulevirtide is unlikely to succeed as a stand-alone treatment and calls for combination regimens that restore antiviral immunity.

Hepatitis B and C prevention programs improve detection, treatment, and liver outcomes, but screening, care access, and implementation gaps remain.

Real-world data show patients with MASH reach cirrhosis in just 16 months, fueling calls for wider use of fibrosis biomarkers like FIB-4.

The US is close to eliminating hepatitis B in children, but chronic adult infection and a shifting vaccine policy threaten that progress.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

Heiner Wedemeyer, MD, offered an unflinching assessment of viral hepatitis medicine, celebrating landmark breakthroughs while issuing a clear warning that the field is failing the populations it set out to protect.

New data highlight pevifoscorvir’s potent antiviral activity and sustained hepatitis B antigen suppression lasting up to 96 weeks after treatment.

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes data remain critical gaps.

Phase 2 data for DD01 and pemvidutide show liver-directed MASH benefits beyond weight loss, with strong tolerability heading into phase 3.

Full results from the pivotal B-Well 1 and B-Well 2 phase 3 trials confirm that bepirovirsen delivers statistically significant functional cure rates in chronic hepatitis B.